The company reinforces its role within Spain’s MedTech ecosystem as part of its growth and international expansion strategy

Madrid, Spain — 2EyesVision, a company specialized in visual simulation technologies applied to ophthalmology, announces its incorporation into Fenin, the Spanish Federation of Healthcare Technology Companies, the leading organization representing the MedTech sector in Spain.

This milestone marks a significant step in the company’s evolution, aligned with its growth, consolidation, and international expansion strategy. Becoming part of Fenin will enable 2EyesVision to strengthen its institutional presence, contribute to the advancement of the sector, and actively collaborate in initiatives that promote technological innovation in healthcare.

What is Fenin?

The Spanish Federation of Healthcare Technology Companies (Fenin) is the main organization representing the MedTech industry in Spain. It serves as a key bridge between companies, public administrations, and healthcare institutions, promoting innovation and improving the quality and efficiency of the healthcare system. Fenin supports the adoption of advanced medical technologies, encourages best practices, and plays a central role in regulation, internationalization, and knowledge generation. Through its working groups and initiatives, it fosters collaboration across the ecosystem, helping drive the transformation of healthcare and ensuring better access to innovative solutions for professionals and patients.

Strategic implications

By joining Fenin, 2EyesVision reinforces its commitment to shaping the future of ophthalmology through innovation, collaboration, and clinical excellence. This step positions the company within a network of leading healthcare technology players, opening new opportunities for partnerships, knowledge exchange, and market expansion. For clinicians, it means continued access to cutting-edge tools that improve decision-making and patient outcomes. For partners and institutions, it reflects a company aligned with industry standards, actively contributing to the evolution of healthcare. For investors, it signals maturity, credibility, and integration within a key strategic ecosystem driving MedTech growth in Spain and beyond. 2EyesVision continues to advance its mission of bringing innovative solutions closer to eyecare professionals and patients, enabling more informed clinical decisions and enhancing the pre-surgical experience.

“Joining Fenin is an opportunity to help shape the future of healthcare technology in Spain from within the ecosystem—sharing knowledge and contributing to a more precise, personalized, and evidence-based ophthalmology” said Carlos Dorronsoro, CEO of 2EyesVision.

This membership also strengthens the company’s commitment to quality standards, sector collaboration, and the development of a more innovative and sustainable healthcare environment.

Want to learn more about 2EyesVision updates?

Discover more news and insights on EyesVision

Copenhagen, 12 September 2025 – At ESCRS iNovation® Day, held on 12 September 2025 at the Bella Center in Copenhagen, SimVis Gekko was recognized by the ophthalmic community as the emerging technology with the greatest potential impact on clinical practice and patient outcomes. During her talk, “SimVis Gekko: Simulation of Multifocal Corrections in the Clinic,” Prof. Susana Marcos presented our visual simulation technology and secured 69% of audience votes for potential impact.

iNovation® Day is the innovation forum preceding the main ESCRS Congress, bringing together doctors, industry leaders, investors, and emerging companies to showcase breakthrough technologies in ophthalmology.

“As part of iNovation, we were honored to see the community recognize SimVis Gekko’s real potential,” said Prof. Susana Marcos. “Earning 69% of votes confirms that visual simulation is not just a concept — it’s becoming a clinical imperative.”

This recognition underscores how SimVis Gekko bridges advanced optics and clinical decision-making, helping ophthalmologists and patients preview vision outcomes with different IOLs before surgery. Its intuitive, binocular simulation brings clarity, trust, and precision to preoperative consultations.

Why this matters

– Community validation: Being voted top emerging technology by peers highlights the trust and expectation placed in SimVis Gekko’s future relevance.

– Clinical relevance: The technology is not just theoretical; it delivers tangible support in IOL counseling, expectation management, and patient satisfaction.

– Strategic momentum: This award strengthens 2EyesVision’s positioning as a front-runner in ophthalmic innovation and reinforces confidence from clinicians, partners, and investors.

About ESCRS iNovation® Day

ESCRS iNovation® Day is held immediately before the ESCRS Congress and focuses on innovation, emerging companies, and future trends in ophthalmology. In 2025, it took place on 12 September at the Bella Center, Copenhagen.

Want to learn more?

Discover how SimVis Gekko is shaping ophthalmology:

Interested in investing in 2EyesVision?

Visit our Investors Page:

2EyesVision receives two key honors at the Biophotonics for Eye Research conference in Granada, spotlighting the role of SimVis Gekko in improving IOL selection and patient care

Granada, Spain – Innovation in ophthalmology goes beyond devices—it’s about improving decisions that impact patient outcomes. At BER2025 – Biophotonics for Eye Research, held June 4–6 in Granada, Spain, 2EyesVision received two major recognitions for its contributions to the field of visual simulation and intraocular lens (IOL) selection. These honors highlight the growing scientific validation of SimVis Gekko and its value in clinical and surgical planning. SimVis Gekko is a binocular visual simulator that enables patients and surgeons to preview the visual outcomes of different IOLs—before surgery. This real-time, real-world simulation offers a personalized experience that helps assess visual function, manage expectations, and educate patients on the impact of multifocal, monofocal, or EDOF lenses. Unlike virtual reality or static tools, SimVis Gekko delivers dynamic optical accuracy with clinical relevance.

At this year’s BER2025, two researchers from 2EyesVision were recognized for their outstanding contributions:

• Alejandra Varea received a Travel Grant for her work on validating clinical applications of SimVis.
• Petros Papadogiannis was awarded Best Poster for his study on halo size evaluation using SimVis Gekko.

“These recognitions not only reflect the quality of our team’s work, but also the impact of SimVis Gekko in advancing personalized visual care,” said Dr. Carlos Dorronsoro, CEO of 2EyesVision.

SimVis Gekko is helping ophthalmologists worldwide empower patients and improve surgical outcomes. Contact us to learn how this solution can enhance your preoperative workflow.

Are you looking for a way to personalize IOL selection and reduce uncertainty in surgical outcomes?

Discover how SimVis Gekko can help you deliver a more transparent, patient-centered preoperative experience—grounded in real vision, not estimates. Contact our team to explore the solution.

Prof. Susana Marcos will present the latest breakthroughs in visual simulation at a key global event

London, United Kingdom – 2EyesVision continues to strengthen its global presence in ophthalmology innovation. On June 5, 2025, Prof. Susana Marcos, co-founder of 2EyesVision, will present SimVis Gekko2 at the AECOS Innovation Forum in London. This invitation marks the recognition of SimVis Gekko2 as a reference in surgical decision-making, offering real-time simulation of visual outcomes before cataract or presbyopia surgery. The event brings together top experts, surgeons, and innovators committed to advancing patient-centered care.

A key presence at AECOS London 2025

Prof. Susana Marcos will speak at the AECOS Innovation Forum in the Ballroom Foyer of the Park Plaza Riverbank Hotel. Her presentation will focus on how SimVis Gekko2 is redefining the preoperative experience by allowing patients to preview their vision with different IOLs in real time. This visual simulation empowers patients to actively participate in the decision-making process, moving beyond traditional explanations toward a data-driven, collaborative approach. By aligning expectations and outcomes, it fosters trust and leads to more confident, personalised surgical choices.

About AECOS: a global platform for innovation

AECOS (American-European Congress of Ophthalmic Surgery) is a leading society that unites surgeons, industry leaders, investors and entrepreneurs to advance anterior segment care. Established in 2011, it fosters innovation through collaboration, advocacy and education. As a 501(c)(6) nonprofit, AECOS has led efforts with the FDA and CMS on surgical guidance, while supporting pioneering technologies like corneal cross-linking and laser refractive cataract surgery.

“We’re excited to be part of AECOS and proud that SimVis Gekko2 continues to receive recognition among global leaders in ophthalmology,” says Prof. Susana Marcos, co-founder of 2EyesVision.

Participation in AECOS positions SimVis Gekko2 as one of the technologies shaping the next chapter of vision care. It reinforces 2EyesVision’s role as a bridge between cutting-edge science and real-world clinical application.

Are you looking to bring patient-centered innovation into your surgical practice?

Learn how SimVis Gekko2 can help elevate your decision-making and patient satisfaction

Are you interested in investing in SimVis Gekko2 and shaping the future of personalized eye care?

SimVis Gekko2 isn’t just transforming patient care — it’s a powerful growth opportunity. Ready to invest?

The visual simulator from 2EyesVision captures attention at the French Society of Ophthalmology congress, with live demos, expert sessions, and strong interest from professionals

Paris, France — 2EyesVision continues to expand its European presence as SimVis Gekko lands in France for the SFO 2025 congress, in partnership with Ophta-France. The booth attracted a vibrant flow of eye care professionals, eager to explore how this visual simulation technology is changing the game in IOL selection.

What is SimVis Gekko?

SimVis Gekko is a groundbreaking binocular visual simulator developed by 2EyesVision, designed to help patients experience how they will see with different intraocular lens options — before surgery. It supports more accurate IOL selection and improves both clinical outcomes and patient satisfaction in cataract and presbyopia treatments.

An event full of energy and innovation

At booth F34, the SimVis Gekko demos became a center of attention, sparking curiosity and conversation among ophthalmologists, surgeons, and vision care specialists. Live demonstrations showcased the device’s ability to simulate various lens options in real time — a disruptive approach to shared decision-making in refractive and cataract surgery.

Expert insights at the MEDLAB session

One of the highlights of the event was the MEDLAB session on May 11, where Dr. Camille Bosc shared clinical perspectives on how SimVis Gekko is transforming the way eye care professionals approach IOL selection. The session underscored the need for personalized tools in ophthalmology and how simulation is becoming central to better patient communication and surgical planning.

Gratitude and future outlook

“We are proud to support Ophta-France at this key event,” said Carlos Dorronsoro, 2EyesVision CEO. “The energy at the booth confirmed what we believe — that visual simulation has a growing role in the future of ophthalmology.”

About Ophta-France

Ophta-France is a French company specialized in ophthalmic surgery solutions. As part of the AEM Group, it distributes high-quality medical devices for cataract, retina, and refractive procedures, including intraocular lenses, surgical instruments, and diagnostic tools. Based near Rennes, it partners with global leaders like HumanOptics and Oertli to bring innovative technologies to eye care professionals across France.

About SFO 2025

SFO 2025, the 131st Congress of the Société Française d’Ophtalmologie, was held in Paris from May 10–12, 2025. It is one of Europe’s leading ophthalmology events, gathering thousands of professionals to explore clinical advances, surgical techniques, and medical technologies. The congress featured expert-led sessions, exhibitions, and hands-on demonstrations, including the debut of SimVis Gekko, a breakthrough visual simulator. With strong industry participation, SFO 2025 highlighted the future of personalized eye care and innovation in IOL selection, diagnostics, and patient communication.

With strong engagement from the French ophthalmology community, 2EyesVision reinforces its mission to bring cutting-edge visual simulation technology closer to clinicians and patients across Europe.

Curious to see what your patients will actually see?

Visit us at our next event or get in touch to discover how SimVis Gekko can support better IOL decisions in your practice.

 

Follow us in LinkedIn:

Presented by Dr. Jay Pepose, SimVis offers a new way for patients to experience their vision before presbyopia or cataract surgery—empowering informed decisions.

Maui, Hawaii, USA – Presbyopia-correcting intraocular lenses (IOLs) are advancing rapidly, but the preoperative patient experience has long lacked tools for meaningful personalization. That changed at the Hawaiian Eye & Retina 2025 conference, where Dr. Jay Pepose presented SimVis, a technology developed by 2EyesVision that allows patients to preview how they will see with different IOLs—before surgery. This new capability could transform clinical workflows and significantly improve patient confidence and satisfaction in visual outcomes.

SimVis is an advanced visual simulator that enables real-world, binocular simulation of multifocal, monofocal, EDOF, or mixed intraocular lenses. Unlike virtual reality or screen-based estimations, SimVis projects actual optical patterns through wearable devices, providing a dynamic and realistic preview of postoperative vision. This allows patients to “test-drive” their vision with various lenses, supporting truly informed decision-making in refractive and cataract surgery.

At this year’s Hawaiian Eye & Retina Conference in Hawaii, Dr. Jay Pepose delivered a compelling presentation on the clinical value of SimVis. He emphasized how the technology fills a critical gap in current preoperative assessments.

“SimVis allows patients to test-drive their IOL options preoperatively, offering a realistic preview of postoperative outcomes,” said Dr. Pepose. “It empowers both patients and surgeons.”

SimVis enhances more than just technical accuracy; it supports better relationships between surgeons and patients by reducing uncertainty and aligning expectations. For patients, understanding what to expect before surgery reduces anxiety and increases trust in the chosen solution. For clinics, it strengthens the premium offering and adds value to consultations.

Are you looking for a solution to enhance preoperative decision-making in your ophthalmology practice?

Contact us to learn how SimVis can help you bring clarity and confidence to your patients—before they enter the OR.